A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

August 2, 2017

Study Completion Date

August 2, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

SPX-101

Inhalation solution twice daily for 7 days.

Trial Locations (1)

Saint Michael's Hospital, Toronto

All Listed Sponsors

lead

Spyryx Biosciences, Inc.

INDUSTRY

NCT03056989 - A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter